Valbenazine for Huntington's Disease
Trial Summary
What is the purpose of this trial?
This trial is testing the safety of valbenazine, a medication that helps control involuntary movements in patients with Huntington disease who suffer from chorea. Valbenazine works by balancing brain chemicals to reduce these unwanted movements.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you cannot have used a VMAT2 inhibitor within 30 days before starting the trial.
What data supports the effectiveness of the drug Valbenazine for Huntington's Disease?
Valbenazine is a drug that has been approved for treating tardive dyskinesia, a movement disorder, and is being studied for its potential to help with chorea (involuntary movements) in Huntington's disease. It is similar to tetrabenazine, which is already used for Huntington's disease, suggesting it might also be effective for this condition.12345
Is Valbenazine safe for humans?
Valbenazine, also known as Ingrezza, is approved in the USA for treating tardive dyskinesia and has shown a better short-term side effect profile compared to similar drugs. However, long-term safety data is still being gathered, and its full safety profile will be clearer with more real-world use.12356
How is the drug Valbenazine unique for treating Huntington's disease?
Research Team
Chief Medical Officer
Principal Investigator
Chief Medical Officer
Eligibility Criteria
This trial is for individuals with Huntington's Disease and chorea who either completed a prior study (NBI-98854-HD3005) or have not used VMAT2 inhibitors in the last 30 days. Participants must be able to walk, understand English, consent to the study, and agree to use contraception if of childbearing potential.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive valbenazine for the treatment of chorea associated with Huntington disease
Extended Maintenance
Participants in the US have the option to continue valbenazine administration for up to 104 additional weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Valbenazine
Valbenazine is already approved in United States for the following indications:
- Tardive dyskinesia
- Chorea associated with Huntington's disease
Find a Clinic Near You
Who Is Running the Clinical Trial?
Neurocrine Biosciences
Lead Sponsor
Kyle W. Gano
Neurocrine Biosciences
Chief Executive Officer since 2024
PhD in Pharmacology
Dr. Sanjay Keswani
Neurocrine Biosciences
Chief Medical Officer
MD
Huntington Study Group
Collaborator